Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2016 October;64(5) > Minerva Cardioangiologica 2016 October;64(5):542-51

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

MINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  


Minerva Cardioangiologica 2016 October;64(5):542-51

lingua: Inglese

Current knowledge and future perspectives regarding stented valves

Giuseppe SANTARPINO, Jurij M. KALISNIK, Theodor FISCHLEIN, Steffen PFEIFFER

Department of Cardiac Surgery, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany


PDF  


Aortic valve bioprostheses are commonly implanted in the current era (also in younger patients) as they may obviate the need for anticoagulation while providing better hemodynamic performance and a more favorable quality of life. The steady increase in the use of biological valves has prompted the development of several different models of conventional stented bioprostheses. At present, there are four main types of stented aortic bioprostheses that compete in the market: the LivaNova Crown PRT (LivaNova Group, Burnaby, Canada), the St. Jude Medical Trifecta (St. Jude Medical, St. Paul, MN, USA), the Carpentier-Edwards Perimount Magna Ease (Edwards Lifesciences, Irvine, CA, USA), and the Medtronic Mosaic Ultra (Medtronic, Inc., Minneapolis, MN, USA). The purpose of this review is to describe the features of these bioprosthetic valve models and to compare the data provided by the manufacturers with those derived from the available literature.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

giuseppe.santarpino@klinikum-nuernberg.de